Université Paris-Saclay, CNRS, Institut Galien Paris-Saclay, 91400 Orsay, France.
Université Paris-Cité, Inserm, UMR-S 976 HIPI, Service de Dermatologie, Hôpital Saint Louis, 75010 Paris, France.
Int J Pharm. 2023 Apr 25;637:122870. doi: 10.1016/j.ijpharm.2023.122870. Epub 2023 Mar 21.
Innovative Pickering emulsions co-encapsulating two active pharmaceutical ingredients (API) were formulated for a topical use. An immunosuppressive agent, either cyclosporine A (CysA) or tacrolimus (TAC), was encapsulated at high drug loading in biodegradable and biocompatible poly (lactic-co-glycolic acid) (PLGA) nanoparticles (NP). These NP stabilized the oil droplets (Miglyol) containing an anti-inflammatory drug, calcitriol (CAL). The influence of the API on the physico-chemical properties of these emulsions were studied. Emulsions formulated with or without API had a similar macroscopic and microscopic structure, as well as interfacial properties, and they exhibited a good stability for at least 55 days. The emulsions did not alter the viability of human keratinocytes (HaCaT cell line) after 2 and 5 days of exposure to NP concentrations equivalent to efficient API dosages. Thus, these new Pickering emulsions appear as a promising multidrug delivery system for the treatment of chronical inflammatory skin diseases.
创新性的 Pickering 乳液共包封两种活性药物成分 (API)，用于局部使用。免疫抑制剂环孢素 A (CysA) 或他克莫司 (TAC) 以高载药量包封在可生物降解和生物相容的聚 (乳酸-共-羟基乙酸) (PLGA) 纳米颗粒 (NP) 中。这些 NP 稳定了含有抗炎药物骨化三醇 (CAL) 的油滴 (Miglyol)。研究了 API 对这些乳液的物理化学性质的影响。含有或不含有 API 的乳液具有相似的宏观和微观结构以及界面性质，并且在至少 55 天内表现出良好的稳定性。这些乳液在暴露于相当于有效 API 剂量的 NP 浓度 2 和 5 天后，并未改变人角质形成细胞 (HaCaT 细胞系) 的活力。因此，这些新的 Pickering 乳液似乎是一种有前途的多药物递送系统，可用于治疗慢性炎症性皮肤病。
